Lactobio appoints new CCO to drive international growth
Lactobio, a Danish biotech company developing unique microbial solutions, has appointed Erik Rasmussen as Chief Commercial Officer effective February 2020.
As CCO of Lactobio, Erik Rasmussen will be responsible for the overall sales and marketing strategy, expanding Lactobio’s business in new markets and driving the company’s international growth further.
“It’s a fantastic opportunity and a great responsibility to take on this role at one of the most exciting biotech companies in the world. With the growing market in probiotics and increasing skin problems throughout the world, Lactobio is providing innovative microbial solutions. I look forward to bringing my expertise to the company, ensuring the continued growth of the company and build upon the current success,” says Erik Rasmussen.
As former International Sales & Technical Marketing Manager at Cell Biotech, Erik has extensive commercial experience working within the pharmacy and probiotics market.
Søren Kjærullf, CEO of Lactobio says “we are pleased to welcome Erik to boost Lactobio’s expansion to new markets and further revenue growth. Erik’s experience and solid track record will help us to continue to scale our business globally”.
Lactobio develops cosmeceuticals, dietary supplements and live biotherapeutic products to target pathogens and microbiome dysfunctions associated with specific diseases.
Lactobio has a state-of-the-art BSL2 Microbiology Laboratory where our research scientists with PhDs in microbiology, biotechnology and biochemistry identify, select and grow the best probiotic strains to fight pathogenic bacteria, including multiresistant bacteria.
Management and board
CEO Søren Kjærulff, PhD
Former Senior Director of Biopharma R&D at Novozymes A/S.
COO Charlotte Vedel, PhD
Former Vice President of IP, Dupont.
CCO Erik Rasmussen
Former International Sales & Marketing Manager at Cell Biotech.
Chairman of the board Per Falholt
Investor in Lactobio and former CSO and EVP of Novozymes A/S.
For further information please contact:
Søren Kjærullf, PhD, CEO
Mobile: +45 3131 8659